Verrica Pharmaceuticals Announces Presentation of Three Posters Featuring Positive Preliminary Topline Results of VP-315 for the Treatment of Basal Cell Carcinoma at the 2025 Winter Clinical Dermatology Conference

Core Insights - Verrica Pharmaceuticals presented promising clinical data for VP-315, an investigational therapy for basal cell carcinoma (BCC), showcasing a 97% calculated objective response rate (ORR) [1][4] - The Phase 2 study results indicate significant safety and efficacy, with 51% of tumors achieving complete histological clearance and an average tumor size reduction of 71% for residual tumors [3][4] - The company aims to position VP-315 as a non-surgical first-line treatment option for BCC, addressing a high unmet need in the market [5][9] Study Details - The Phase 2 study is a multicenter, open-label, dose-escalation trial involving 92 adult subjects with biopsy-proven BCC [6] - The study's Part 2 focused on evaluating dosing regimens and included safety and histological clearance data from 82 patients with a total of 91 tumors [2][3] - No treatment-related serious adverse events were reported, with most adverse events being mild to moderate [3] Future Plans - The company plans to request an End-of-Phase 2 meeting with the FDA in the first half of 2025 to discuss the development path for VP-315 [4][5] - Genomic and T-cell immune response data are expected to be available in the first quarter of 2025 [4] Market Opportunity - Basal cell carcinoma is the most common cancer in the U.S., with approximately 3-4 million diagnoses annually, highlighting a significant market opportunity for new treatment options [9] - VP-315 is viewed as a potential multi-billion-dollar commercial opportunity for the company, aiming to provide a non-invasive alternative to traditional surgical treatments [5][9]